Related Experiment Video
Updated: Jun 21, 2026
08:25
Heterotopic Mucosal Engrafting Procedure for Direct Drug Delivery to the Brain in Mice
Published on: July 16, 2014
Recent advances in pharmacologic neuroprotection.
Jean Mantz1, Vincent Degos, Christophe Laigle
1Department of Anesthesia, Beuajon University Hospital, Clichy, France. jean.mantz@bj.aphp.fr
European Journal of Anaesthesiology
|July 21, 2009
Summary
Despite advances in understanding brain ischemia, neuroprotective drugs have shown limited success in clinical trials for acute ischemic stroke. Future strategies may involve combined therapies and rigorous trial designs.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Medicine
Background:
- Continued progress in understanding brain ischemia and reperfusion pathophysiology.
- Limited clinical success of pharmacological neuroprotection for acute ischemic stroke.
- Numerous clinical trials for neuroprotectants have failed to show significant benefits.
Purpose of the Study:
- To review the limited clinical impact of pharmacological neuroprotection in brain ischemia.
- To explore potential future therapeutic strategies for ischemic stroke.
- To discuss the role of anesthetics in perioperative neuroprotection.
Main Methods:
- Review of existing literature on neuroprotection for brain ischemia.
- Analysis of clinical trial outcomes for neuroprotective agents.
- Discussion of combined therapeutic approaches and trial design.
Main Results:
- Most clinical trials testing neuroprotectants for acute ischemic stroke have yielded negative results.
- Current pharmacological approaches have had minimal clinical impact.
- The efficacy of anesthetics as neuroprotectants in the perioperative setting is not yet established.
Conclusions:
- Future therapeutic strategies for brain ischemia may involve combining physiologic (e.g., oxygen, hypothermia), pharmacologic (e.g., erythropoietin derivatives), and thrombolytic therapies.
- Rigorous clinical trial design is crucial for future research.
- Further investigation is needed to establish the role of anesthetics in perioperative neuroprotection.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:26Neurochemical Transmission: Sites of Drug Action
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).